SMAR Daily Industry News

New Study Finds 75% CTE Prevalence in Deceased NFL Players

A recent study conducted by researchers at Boston University, in collaboration with Mass General Brigham and the Concussion & CTE Foundation, has identified a significant prevalence of chronic traumatic encephalopathy (CTE) among deceased former National Football League (NFL) players. Published in JAMA Network Open, the analysis indicates that nearly 75% of NFL players who passed away between 2008 and 2023 exhibited neuropathology consistent with the disease.

This research represents a methodological advancement over previous attempts to quantify CTE prevalence. An earlier study from 2026 faced scrutiny due to selection bias, as it relied heavily on brain donations from individuals who were more likely to have experienced symptoms while alive. To address these concerns, the current research team expanded their scope, analyzing 2,362 cases. This dataset combined 396 brain donations with records from 1,966 deceased players who did not donate their brains, utilizing data from the National Death Index to create a more representative sample.

CTE is a neurodegenerative condition linked to repetitive head impacts. Currently, it can only be confirmed through postmortem examination. While the study provides a clearer picture of the disease's scale among the deceased, lead author Julia Gallini, a PhD candidate at the Boston University School of Public Health, emphasized that these findings do not predict the prevalence of CTE in living former players or active athletes. However, the 75% figure is stark when contrasted with the less than 1% prevalence found in community brain banks.

From an analytical perspective, this study underscores the limitations of current diagnostic capabilities. Because CTE remains a postmortem diagnosis, the medical and sports communities face a significant data gap regarding the health of living athletes. For the LIMS and medical informatics sectors, this highlights a critical need for better longitudinal data management and diagnostic software capable of identifying biomarkers or early indicators of neurodegeneration in living patients. The focus is shifting from simply documenting mortality to developing predictive models that could eventually allow for intervention during an athlete's career.

The implications for the sports industry are substantial. The NFL has stated it continues to implement strategies aimed at reducing concussions and head impacts, while the NFL Players Association has characterized such research as vital for understanding the long-term consequences of the sport. Former NFL quarterback Matt Hasselbeck, who serves as an ambassador for the DIAGNOSE CTE study, noted that the data must be leveraged to improve safety protocols for future generations.

The broader context of this research includes a history of legal and medical scrutiny regarding head trauma in professional sports. In 2013, the NFL settled a lawsuit for $765 million with retired players regarding the long-term effects of head trauma, and in 2018, the National Hockey League reached a $19 million settlement with retired players. As researchers continue to refine their methodologies, the focus will likely remain on translating these pathological findings into actionable clinical tools for the living.

Why it matters

The study provides a more statistically robust understanding of CTE prevalence in deceased NFL players, highlighting an urgent need for diagnostic tools that can identify the disease in living patients.

FAQ

What is CTE and how is it diagnosed?
CTE is a neurodegenerative disease associated with repetitive head impacts; it can currently only be definitively diagnosed after death.

How did this study address previous criticisms regarding selection bias?
Researchers included data from 1,966 deceased players who did not donate their brains, alongside 396 brain donations, to create a more representative sample than previous studies.

Does this study predict CTE in active NFL players?
No, the researchers explicitly stated that the findings apply only to former NFL players after death and do not predict the prevalence in living or active players.

Source: Insurance Journal. See the original source for full details.